Press "Enter" to skip to content

Permission to use two more vaccines against corona virus in China

Two more vaccines were approved for use in China. China National Medicines Association, CanSino Biologics and the state-affiliated Sinopharm companies have been given conditional approval for their vaccines.

Both vaccines have been used in a limited way within the scope of emergency use approval for a while. thus The number of vaccines administered on the masses in China has increased to four.

The vaccine of CanSino, the first single-dose vaccine candidate produced in China, reaches an efficiency rate of 65.28 percent after 28 days, according to the company’s data.

The company noted that the vaccine, which can be stored between 2 and 8 degrees Celsius, will provide convenience, especially in regions where health services are not sufficient.

Download the NTV application, be informed about the developments


CanSino vaccine, one of the adenovirus (viral vector) vaccines, grip It creates immunity by injecting a virus that causes a similar disease into the body, supported by coronavirus protein after genetic intervention.

Although the microorganisms in the vaccine are alive, they cannot cause disease in humans because they are weakened. Oxford/AstraZeneca, Sputnik V ve Johnson & Johnson‘s vaccines are produced in a similar way.

Sinopharm’s new vaccine, on the other hand, has an efficiency of 72.5 percent, according to the company’s data. The second vaccine is an inactive vaccine, like Sinopharm’s first approved vaccine. In the inactive vaccine, which is a traditional method, the virus is killed, disintegrated and inactivated, and the immune system is stimulated without harming the body.


Neither company has yet published final results on the safety and efficacy of vaccines.

Developed with the contribution of the Military Academy of Sciences, the CanSino vaccine received an emergency use permit last June to be used only in the army and has been administered to 150 thousand military personnel so far. Sinopharm and Sinovac The company, which does not have as large a production capacity, is expected to produce 300 million doses per year.


On the other hand, Russia cut the price of the Sputnik V vaccine by half, to $ 12. In the statement made by the government, it was pointed out that the price of the vaccine was determined by the state because it was included in the “vital drugs” list.

Trade Minister Denis Manturov stated that the price reduction is possible thanks to improvements and optimization in industrial production of the vaccine. The minister noted that the significant increase in the amount produced with the introduction of mass vaccination in Russia also played a role in the price reduction.

Manturov added that the new price will only apply to vaccination campaigns within Russia.

Sputnik V was the first registered vaccine against coronavirus in the world by obtaining a use permit in Russia in August. Russia’s consent to the vaccine before the Phase 3 research results were completed led to the international suspicion of the vaccine.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *